Here are what the editors at HealthDay consider to be the most important developments in Dermatology for September 2020. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Hospital Admissions Not Related to COVID-19 Fell in Early 2020
WEDNESDAY, Sept. 30, 2020 (HealthDay News) — Non-COVID-19 hospital admissions decreased considerably with the onset of COVID-19, with declines generally similar across patient demographic subgroups from February to April 2020, according to a report published online Sept. 24 in Health Affairs.
Cancer Mortality Higher for U.S. Counties With Persistent Poverty
WEDNESDAY, Sept. 30, 2020 (HealthDay News) — U.S. counties with persistent poverty (≥20 percent of residents in poverty since 1980) have higher rates of cancer mortality, according to a study published online Sept. 30 in Cancer Epidemiology, Biomarkers & Prevention.
Private Health Plans Pay Hospitals 247 Percent of Medicare
MONDAY, Sept. 28, 2020 (HealthDay News) — During 2018, prices paid to hospitals by privately insured patients averaged 247 percent of what Medicare would have paid, according to a study from the RAND Corporation.
Oral Steroids May Raise Risks for Diabetes, HTN, VTE in Children
WEDNESDAY, Sept. 23, 2020 (HealthDay News) — Children with current glucocorticoid exposure have increased risks for diabetes mellitus, hypertension, and venous thromboembolism (VTE), according to a study published online Sept. 9 in the American Journal of Epidemiology.
Impact of Psoriasis Explored for Hospital Outcomes of Acute MI
MONDAY, Sept. 21, 2020 (HealthDay News) — Myocardial infarction (MI) events may occur earlier in life in patients with psoriasis, which in turn may affect hospital outcomes, according to a study published online Sept. 11 in the Journal of the American Heart Association.
Depression Common Among Psoriasis Patients
FRIDAY, Sept. 18, 2020 (HealthDay News) — Depression is common among patients with psoriasis, according to a study published online Sept. 14 in Dermatology.
Cancer Incidence Up for Adolescents and Young Adults
THURSDAY, Sept. 17, 2020 (HealthDay News) — Among adolescents and young adults (AYAs), cancer incidence increased during 2007 to 2016, according to a report published online Sept. 17 in CA: A Cancer Journal for Clinicians.
Spironolactone Not Tied to Breast Cancer Recurrence
WEDNESDAY, Sept. 16, 2020 (HealthDay News) — Spironolactone is not independently associated with increased breast cancer recurrence, according to a study published in the October issue of the Journal of the American Academy of Dermatology.
Lipid-Rich Necrotic Core Linked to Psoriasis Severity
TUESDAY, Sept. 15, 2020 (HealthDay News) — For patients with psoriasis, lipid-rich necrotic core (LRNC) is associated with psoriasis severity and cardiovascular risk factors and is reduced for those patients receiving biologic therapy, according to a study published online Sept. 15 in Circulation: Cardiovascular Imaging.
Widespread Avoidance of Medical Care Found Due to COVID-19 Concerns
THURSDAY, Sept. 10, 2020 (HealthDay News) — There was widespread reporting of avoidance of medical care due to COVID-19-related concerns in June 2020, according to research published in the Sept. 11 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Shift Seen to Newer Agents to Treat Psoriasis
THURSDAY, Sept. 10, 2020 (HealthDay News) — Phototherapy use for psoriasis decreased from 2005 to 2018, while use of biologics increased, according to a research letter published online Sept. 4 in Dermatologic Therapy.
Permanent Hair Dye Not Linked to Cancer Risk, Mortality
TUESDAY, Sept. 8, 2020 (HealthDay News) — Use of permanent hair dye is not associated with the risk for most cancers or cancer mortality, according to a study published online Sept. 2 in The BMJ.
Some Lupus Erythematosus Cases Tied to Drug Exposure
FRIDAY, Sept. 4, 2020 (HealthDay News) — Some cases of subacute cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) are drug-induced, according to a study published online Sept. 2 in JAMA Dermatology.
Benefit of Adjuvant Dabrafenib + Trametinib Persists in Melanoma
FRIDAY, Sept. 4, 2020 (HealthDay News) — For patients with stage III melanoma with BRAF V600E or V600K mutations, 12 months of adjuvant dabrafenib plus trametinib results in increased survival without relapse or distant metastasis at five years, according to a study published online Sept. 2 in the New England Journal of Medicine.
Copyright © 2020 ScoutNews, LLC. All rights reserved.